CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Related Organizations›
Sphere Bio›
Library
Sphere Bio

Sphere Bio

Related Organization / UnitPart ofFluidic Sciences

Sphere Bio builds Cyto-Mine picodroplet platforms for single-cell screening, sorting, and dispensing in antibody and cell-line discovery.

Operating headquarters
Royston, GB🇬🇧
Founded
2010
Loading
Overview
Relationships
Compare
Employees
Library

Sphere Bio - Library

Official pages and third-party coverage in one index.

spherebio.com·22 items across 21 mapped pages · Crawled Oct 3, 2026·

Topics

Publication type

Content origin
Row density

Official pages and third-party coverage in one index

Product

6 pages
  1. Cyto-Cellect® Fc Fusion Assay Kit launched to expedite cell line development for fusion proteins/launch-cyto-cellect-fc-fusion-assay-kit

    Novel assay offers a highly sensitive and specific method to detect recombinant proteins containing the human IgG Fc domain.

  2. Cyto-Cellect® Human IgG Kappa and Viability Assay Kit launched for efficient single-cell selection/cyto-cellect-human-igg-kappa-and-viability-assay-kit-launched

    Today, we launched the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit, the first multiplexed assay developed for Cyto-Mine® Chroma.

  3. Cyto-Mine® Chroma announced to accelerate and streamline workflows/cyto-mine-chroma-accerate-streamline-workflow

    Sphere Bio Announces Cyto-Mine® Chroma: the next generation of the single-cell analysis platform with multiplexed assays.

  4. Our products/our-products

    Discover the power of our picodroplets products. High-throughput platforms and consumables for single-cell analysis.

Blog

4 pages
  1. Drug Discovery & Development Virtual Event Series 2024/drug-discovery-development-virtual-event-series-2024

    Join us 21February 2024 at 1:30PM to hear how picodroplet technology can enable high throughput single cell screening and isolation.

  2. Jonathan Dempsey Webinar: Accelerating Cell Line Development From Transfection to Manufacturing 2024/jonathan-dempsey-cell-line-development-webinar-2024

    Discover how you can yield highly productive, scalable, clonal cell lines for developing biopharmaceuticals.

  3. Spotlight Series Q&A: Interview with Denise Emsden, VP of People and Organizational Development/spotlight-series-qa-interview-with-denise-emsden

    Insights from the VP of People and Development. Learn how Denise's 25+ years experience has shaped her career and our company culture.

  4. Spotlight Series Q&A: With our Group Leader of Application Development/sphere-fluidics-spotlight-series-qa-with-our-group-leader-of-application-development

    Spotlight Series Q&A With our Group Leader of Application Development, Elena Shvets. Learn about her role and journey.

Pricing

6 pages
  1. CC Mouse Assay Request a Quote Form/cc-mouse-assay-quote-request

    If you'd like to purchase some of our consumables, fill out this form and let us know what you'd like. We can connect and provide you a quote.

  2. CC Probes Assay Request a Quote Form/cc-probes-assay-quote-request

    To get a quote for our Cyto-Cellect® Probes Assay Kit (Cyto-Cellect® Human IgGκ Detection Kit), fill out this form.

  3. Cyto-Surf® B - Request a Quote Form/cyto-surf-b-quote-request

    If you would like to purchase our Cyto-Surf® B, fill out this form. We can connect and provide you a quote.

  4. Pico-Surf® 2% Pricing Request and Ordering Information/pico-surf-2-pricing-request

    If you'd like to purchase Pico-Surf® (2% (w/w) in Novec™ 7500), fill out this form for pricing and ordering information

Team

1 page
  1. Jonathan Dempsey: Accelerating Cell Line Development From Transfection to Manufacturing 2024/resource/jonathan-dempsey

    Watch our webinar by Jonathan Dempsey: Accelerating Cell Line Development From Transfection to Manufacturing - 2024.

About

3 pages
  1. Events/about-us/events

    Discover the events and conferences we attend, and learn more about the power of picodroplet technology in primary research. Sign up to our mailing list.

  2. Inside Sphere Bio: Building a Culture That Supports Innovation and Collaboration/inside-sphere-bio-building-a-culture-that-supports-innovation-and-collaboration

    Discover how Sphere Bio builds a culture of innovation, collaboration, and care to support a motivated, global team.

  3. Sphere Bio strengthens global commercial teams and establishes direct sales and support channel in North America/global-expansion

    Sphere Bio's global expansion led by new CEO, Dale Levitzke, addresses global demand for the Cyto-Mine® Chroma platform.

Homepage

1 page
  1. Homepage/

    We find, analyze and isolate the most valuable cells with ease and speed. Sphere Bio | Cell Selection, Sorted.

Not yet classified

1 page
  1. spherebio.com/

    We find, analyze and isolate the most valuable cells with ease and speed. Sphere Bio | Cell Selection, Sorted.